AVD
AVD
American Vanguard CorporationIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $150.69M ▲ | $33.51M ▼ | $-28.21M ▼ | -18.72% ▼ | $-0.97 ▼ | $10.75M ▲ |
| Q3-2025 | $119.31M ▼ | $40.72M ▲ | $-12.36M ▼ | -10.36% ▼ | $-0.43 ▼ | $-3.04M ▼ |
| Q2-2025 | $129.31M ▲ | $36.18M ▲ | $-849K ▲ | -0.66% ▲ | $-0.03 ▲ | $8.73M ▲ |
| Q1-2025 | $115.8M ▼ | $34.5M ▼ | $-8.46M ▲ | -7.31% ▲ | $-0.3 ▲ | $200K ▲ |
| Q4-2024 | $165.65M | $92.87M | $-90.43M | -54.59% | $-3.21 | $-11.34M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $12.43M ▼ | $596.54M ▼ | $404.14M ▼ | $192.4M ▼ |
| Q3-2025 | $16.8M ▲ | $655.01M ▲ | $434.02M ▲ | $220.99M ▼ |
| Q2-2025 | $14.48M ▲ | $651.98M ▲ | $421.16M ▲ | $230.82M ▲ |
| Q1-2025 | $11.8M ▼ | $631.59M ▼ | $404.23M ▲ | $227.35M ▼ |
| Q4-2024 | $12.51M | $636.72M | $403.61M | $233.11M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $-104.67M ▼ | $5.95M ▼ | $-1.56M ▼ | $-8.36M ▲ | $-4.37M ▼ | $4.43M ▼ |
| Q3-2025 | $-12.36M ▼ | $12.69M ▲ | $-985K ▼ | $-9.42M ▼ | $2.31M ▼ | $11.27M ▲ |
| Q2-2025 | $-849K ▲ | $-19.26M ▲ | $-611K ▼ | $21.68M ▲ | $2.68M ▲ | $-19.85M ▲ |
| Q1-2025 | $-8.46M ▲ | $-20.58M ▼ | $-446K ▼ | $19.8M ▲ | $-709K ▼ | $-21.03M ▼ |
| Q4-2024 | $-90.43M | $33.77M | $-242K | $-32.28M | $634K | $32.53M |
Revenue by Products
| Product | Q3-2019 | Q4-2019 | Q1-2023 | Q4-2023 |
|---|---|---|---|---|
U S Crop | $0 ▲ | $0 ▲ | $60.00M ▲ | $210.00M ▲ |
U S Non Crop | $0 ▲ | $0 ▲ | $10.00M ▲ | $60.00M ▲ |
Amount Of Herbicides Sold | $50.00M ▲ | $70.00M ▲ | $0 ▼ | $0 ▲ |
Amount Of Insecticides Sold | $40.00M ▲ | $40.00M ▲ | $0 ▼ | $0 ▲ |
Crop | $0 ▲ | $110.00M ▲ | $0 ▼ | $0 ▲ |
Non Crop Including Distribution Of Third Party Products | $20.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
Other Including Plant Growth Regulators And Distribution | $20.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 |
|---|---|---|---|---|
NonUS | $40.00M ▲ | $60.00M ▲ | $60.00M ▲ | $90.00M ▲ |
UNITED STATES | $70.00M ▲ | $70.00M ▲ | $60.00M ▼ | $100.00M ▲ |
Q3 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at American Vanguard Corporation's financial evolution and strategic trajectory over the past five years.
American Vanguard combines a solid revenue base and acceptable gross margins with a long history of accumulated profits, as reflected in retained earnings. It holds strong competitive positions in targeted niche markets, backed by differentiated technologies such as SIMPAS, SmartCartridge, and a broad biologicals portfolio. Its regulatory expertise, integrated manufacturing footprint, and diversified end markets (including professional pest control and turf) add resilience. The company’s active R&D efforts and strategic focus on sustainable and precision agriculture give it exposure to attractive long-term growth themes.
The largest concerns center on current financial performance and cash generation. Operations are presently unprofitable, and free cash flow is negative, even as the company continues to invest and return some cash to shareholders. A meaningful debt load and reliance on intangible assets increase sensitivity to prolonged weak results. The business is tied to cyclical agricultural conditions and subject to regulatory and environmental scrutiny, which can affect product portfolios. Execution risk also looms in areas like manufacturing consolidation, international expansion, and scaling new platforms; missteps could delay the intended benefits and further strain financial resources.
Looking ahead, the company’s prospects hinge on its ability to turn innovation and niche strengths into improved profitability and stronger cash flow. If new products, precision-application systems, and biological solutions gain traction as expected, and if operational efficiency initiatives deliver, financial metrics could recover meaningfully over the next few years. At the same time, the current loss-making position and negative free cash flow warrant a cautious stance on the near term, as there is limited room for extended underperformance without further balance sheet adjustment. The overall picture is one of a strategically interesting business with tangible opportunities, but with execution and financial discipline as critical variables for the future trajectory.
About American Vanguard Corporation
https://www.american-vanguard.comAmerican Vanguard Corporation, through its subsidiaries, develops, manufactures, and markets specialty chemicals for agricultural, commercial, and consumer uses in the United States and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $150.69M ▲ | $33.51M ▼ | $-28.21M ▼ | -18.72% ▼ | $-0.97 ▼ | $10.75M ▲ |
| Q3-2025 | $119.31M ▼ | $40.72M ▲ | $-12.36M ▼ | -10.36% ▼ | $-0.43 ▼ | $-3.04M ▼ |
| Q2-2025 | $129.31M ▲ | $36.18M ▲ | $-849K ▲ | -0.66% ▲ | $-0.03 ▲ | $8.73M ▲ |
| Q1-2025 | $115.8M ▼ | $34.5M ▼ | $-8.46M ▲ | -7.31% ▲ | $-0.3 ▲ | $200K ▲ |
| Q4-2024 | $165.65M | $92.87M | $-90.43M | -54.59% | $-3.21 | $-11.34M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $12.43M ▼ | $596.54M ▼ | $404.14M ▼ | $192.4M ▼ |
| Q3-2025 | $16.8M ▲ | $655.01M ▲ | $434.02M ▲ | $220.99M ▼ |
| Q2-2025 | $14.48M ▲ | $651.98M ▲ | $421.16M ▲ | $230.82M ▲ |
| Q1-2025 | $11.8M ▼ | $631.59M ▼ | $404.23M ▲ | $227.35M ▼ |
| Q4-2024 | $12.51M | $636.72M | $403.61M | $233.11M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $-104.67M ▼ | $5.95M ▼ | $-1.56M ▼ | $-8.36M ▲ | $-4.37M ▼ | $4.43M ▼ |
| Q3-2025 | $-12.36M ▼ | $12.69M ▲ | $-985K ▼ | $-9.42M ▼ | $2.31M ▼ | $11.27M ▲ |
| Q2-2025 | $-849K ▲ | $-19.26M ▲ | $-611K ▼ | $21.68M ▲ | $2.68M ▲ | $-19.85M ▲ |
| Q1-2025 | $-8.46M ▲ | $-20.58M ▼ | $-446K ▼ | $19.8M ▲ | $-709K ▼ | $-21.03M ▼ |
| Q4-2024 | $-90.43M | $33.77M | $-242K | $-32.28M | $634K | $32.53M |
Revenue by Products
| Product | Q3-2019 | Q4-2019 | Q1-2023 | Q4-2023 |
|---|---|---|---|---|
U S Crop | $0 ▲ | $0 ▲ | $60.00M ▲ | $210.00M ▲ |
U S Non Crop | $0 ▲ | $0 ▲ | $10.00M ▲ | $60.00M ▲ |
Amount Of Herbicides Sold | $50.00M ▲ | $70.00M ▲ | $0 ▼ | $0 ▲ |
Amount Of Insecticides Sold | $40.00M ▲ | $40.00M ▲ | $0 ▼ | $0 ▲ |
Crop | $0 ▲ | $110.00M ▲ | $0 ▼ | $0 ▲ |
Non Crop Including Distribution Of Third Party Products | $20.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
Other Including Plant Growth Regulators And Distribution | $20.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 |
|---|---|---|---|---|
NonUS | $40.00M ▲ | $60.00M ▲ | $60.00M ▲ | $90.00M ▲ |
UNITED STATES | $70.00M ▲ | $70.00M ▲ | $60.00M ▼ | $100.00M ▲ |
Q3 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at American Vanguard Corporation's financial evolution and strategic trajectory over the past five years.
American Vanguard combines a solid revenue base and acceptable gross margins with a long history of accumulated profits, as reflected in retained earnings. It holds strong competitive positions in targeted niche markets, backed by differentiated technologies such as SIMPAS, SmartCartridge, and a broad biologicals portfolio. Its regulatory expertise, integrated manufacturing footprint, and diversified end markets (including professional pest control and turf) add resilience. The company’s active R&D efforts and strategic focus on sustainable and precision agriculture give it exposure to attractive long-term growth themes.
The largest concerns center on current financial performance and cash generation. Operations are presently unprofitable, and free cash flow is negative, even as the company continues to invest and return some cash to shareholders. A meaningful debt load and reliance on intangible assets increase sensitivity to prolonged weak results. The business is tied to cyclical agricultural conditions and subject to regulatory and environmental scrutiny, which can affect product portfolios. Execution risk also looms in areas like manufacturing consolidation, international expansion, and scaling new platforms; missteps could delay the intended benefits and further strain financial resources.
Looking ahead, the company’s prospects hinge on its ability to turn innovation and niche strengths into improved profitability and stronger cash flow. If new products, precision-application systems, and biological solutions gain traction as expected, and if operational efficiency initiatives deliver, financial metrics could recover meaningfully over the next few years. At the same time, the current loss-making position and negative free cash flow warrant a cautious stance on the near term, as there is limited room for extended underperformance without further balance sheet adjustment. The overall picture is one of a strategically interesting business with tangible opportunities, but with execution and financial discipline as critical variables for the future trajectory.

CEO
Douglas A. Kaye
Compensation Summary
(Year 2024)
Upcoming Earnings
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2006-04-18 | Forward | 4:3 |
| 2005-04-18 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 70
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BLACKROCK FUND ADVISORS
Shares:2.24M
Value:$5.9M
BLACKROCK INC.
Shares:2.03M
Value:$5.35M
BLACKROCK, INC.
Shares:1.87M
Value:$4.94M
Summary
Showing Top 3 of 182

